Get the Stockscreener App
1.25
1.57%
-0.02
After Hours:
1.25
Climb Bio Inc stock is traded at $1.25, with a volume of 124.94K.
It is down -1.57% in the last 24 hours and up +6.84% over the past month.
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.
See More
Previous Close:
$1.27
Open:
$1.27
24h Volume:
124.94K
Relative Volume:
0.55
Market Cap:
$83.12M
Revenue:
-
Net Income/Loss:
$-64.20M
P/E Ratio:
-0.5814
EPS:
-2.15
Net Cash Flow:
$57,000
1W Performance:
+1.63%
1M Performance:
+6.84%
6M Performance:
-65.47%
1Y Performance:
+0.00%
1-Day Range:
$1.25
$1.325
1-Week Range:
$1.21
$1.37
52-Week Range:
$1.05
$5.47
Climb Bio Inc Stock (CLYM) Company Profile
Name
Climb Bio Inc
Sector
Industry
Phone
1-866-857-2596
Address
20 WILLIAM STREET, WELLESLEY HILLS
Compare CLYM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLYM
Climb Bio Inc
|
1.25 | 83.12M | 0 | -64.20M | 57,000 | -2.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Climb Bio Inc Stock (CLYM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-24 | Initiated | Leerink Partners | Outperform |
Climb Bio Inc Stock (CLYM) Latest News
Jim Cramer on Netflix, Inc. (NFLX): ‘I Bet This One Can Continue to Climb Over the Long Haul’ - Yahoo Finance
Kospi continues to climb gradually amid auto and bio gains - MSN
Tevogen Bio Holdings Stock Is Soaring After Hours: What's Going On? - Benzinga
Hair Transplant System Market Expected to Climb to USD 44.24 Billion by 2032, Rising at 21.6% CAGR - openPR.com
Piper Sandler Remains a Buy on Solid Biosciences (SLDB) - The Globe and Mail
Virtual Cardiology Market Expected to Climb from USD 1.7 Billion in 2025 to USD 4.2 Billion by 2032 - openPR.com
Climb Bio Inc (NASDAQ: CLYM): On Track To A Higher Share Price - Stocksregister
Most active stocks: US stocks with the highest trading volume today - Yahoo
Sugar Prices Climb on Reduced Sugar Output in India - The Globe and Mail
UnitedHealth reports 'unusual and unacceptable' earnings as Medicare costs climb - Endpoints News
3,756 Shares in Climb Global Solutions, Inc. (NASDAQ:CLMB) Purchased by Arrowstreet Capital Limited Partnership - Defense World
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Exec Edge Launches Research Coverage with Initiation Notes on FLD, CLYM, STKS, REX - Yahoo Finance
Happy Joe’s, Sacco climb top industry Movers & Shakers list - Quad Cities Business Journal
CLYM stock touches 52-week low at $1.2 amid market challenges - Investing.com Australia
Climb Bio expands board with two new directors - Investing.com Australia
Climb Bio expands board with two new directors By Investing.com - Investing.com Canada
Climb Bio appoints Kim Cobleigh Drapkin, Bo Cumbo to board - TipRanks
Climb Bio Expands Board with New Director Appointments - TipRanks
Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors - The Manila Times
INmune Bio Inc. Presents Baseline Demographics and Disease Profiles of Participants in the MINDFuL Phase II Study - The Manila Times
Biotech Leaders Join Climb Bio Board: 11 Successful Drug Launches Experience - Stock Titan
Q2 Earnings Estimate for Climb Bio Issued By Leerink Partnrs - The AM Reporter
What is Leerink Partnrs’ Estimate for Climb Bio Q2 Earnings? - Defense World
Bioplastics And Biopolymers Market Key Drivers, Opportunities and Trends | Exactitude Consultancy - Yahoo Finance
Climb Bio to Present at the 24th Annual Needham Virtual Healthcare Conference - The Manila Times
Climb Bio Advances Clinical Trials and Expands Pipeline - TipRanks
Can you use home equity to pay for long-term care? - Yahoo Finance
Climb Bio Fueled Up with Cash, Poised for More Milestones in ’25 – Quarterly Update Report - Yahoo Finance
Climb Bio Fueled Up with Cash, Poised for More Milestones in ’25 – Downloadable Quarterly Update - Yahoo Finance
Citigroup (C) Could Be a Great Choice - Yahoo Finance
Pre-market Movers: PTPI, ACON, HUMA, TNON... - RTTNews
China deals look beyond cancer - BioCentury
Climb Bio Files For Offering Of Common Stock Up To $22.4 MillionSEC Filing - MarketScreener
Climb Bio Reports Fourth Quarter And Year-End 2024 Financial Results And Provides Business Updates - Marketscreener.com
Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates - Yahoo
Conagra to close Michigan plant, impacting 85 jobs - Yahoo Finance
Exclusive: BlackRock expands blockchain-based money market to Solana, in tie-up with startup Securitize - Yahoo Finance
Climb bio SVP Emily Pimblett sells shares worth $1,570 By Investing.com - Investing.com South Africa
Climb bio SVP Emily Pimblett sells shares worth $1,570 - Investing.com India
Why Are Jabil (JBL) Shares Soaring Today - Yahoo Finance
Climb Bio: Meet The Newest Star in Autoimmune Disease Treatment – Initiation Report - Yahoo Finance
Climb Bio (CLYM) Expected to Announce Earnings on Thursday - Defense World
Stock market today: Dow gains 350 points as stocks climb for 2nd day after S&P 500 enters correction - Yahoo Finance
Gossamer Bio shares rise on Q4 earnings beat By Investing.com - Investing.com South Africa
Gossamer Bio shares rise on Q4 earnings beat - Investing.com India
Bio-Key International Inc (BKYI): Major Improvements, Worth A Look - Stocks Register
Sugar Prices Climb on the Prospects for Lower Global Sugar Production - The Globe and Mail
Sugar Prices Climb on the Outlook for Small Sugar Output in India - The Globe and Mail
CLYM stock touches 52-week low at $1.29 amid market challenges - Investing.com Australia
CLYM stock touches 52-week low at $1.29 amid market challenges By Investing.com - Investing.com South Africa
Climb Bio Inc Stock (CLYM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.39%
3.66%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):